Point72 Asset Management
MURA

Point72 Asset Management’s Mural Oncology MURA Stock Holding History

Point72 Asset Management’s Portfolio MURA Stock Details MURA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-108,715
Closed -$340K – 2319
2024
Q3 		$340K Buy
+108,715
New +$354K ﹤0.01% 1687

Other funds holding MURA

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return
SCM
Solas Capital Management Darien, Connecticut $174M AUM 6.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NM
Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RC
RBF Capital San Francisco, California $2.05B AUM 29.64% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Verition Fund Management
Verition Fund Management Greenwich, Connecticut $15.4B AUM 30.69% 1-Year Est. Return

Point72 Asset Management's MURA Position: Q4 2024 in Review

Point72 Asset Management sold out of Mural Oncology (MURA) in Q4 2024, closing a stake of 108,715 shares — an estimated $340K sold.

Point72 Asset Management first reported a position in MURA in Q3 2024 and held it in 1 quarter. The position peaked at $340K in Q3 2024. 76 funds tracked by Wall St. Rank hold MURA as of Q4 2024.

  • Point72 Asset Management reported no remaining Mural Oncology position as of Q4 2024 after selling out during the quarter.
  • Point72 Asset Management sold 108,715 Mural Oncology shares in Q4 2024, an estimated $340K.
  • Point72 Asset Management first reported a position in Mural Oncology in Q3 2024 and held it in 1 quarter.
  • Point72 Asset Management's Mural Oncology position peaked at $340K in Q3 2024.
  • 76 funds tracked by Wall St. Rank held Mural Oncology as of Q4 2024.

Based on Point72 Asset Management's 13F filing for Q4 2024, filed 14 Feb 2025.